NON-SMALL CELL LUNG CARCINOMA: CURRENT TREATMENT STRATEGIES AND EMERGING CHALLENGES
Abstract
Lung cancer is a devastating disease that remains the leading causes of death related to cancer globally. Non-small cell lung cancer is the most prevalent form of lung cancer, comprising approximately 85% of all cases. Platinum-based systemic chemotherapy is commonly used as the standard treatment for non-small cell lung cancer. The treatment of non-small cell lung cancer presents various strategies and challenges. These strategies include targeted therapy, immunotherapy, and combination therapy, aiming to inhibit specific molecular pathways or enhance the patient's immune system response. Despite these advancements, the challenge of resistance to targeted therapies remains a major hurdle for non-small cell lung cancer therapeutics. These challenges include the identification of driver mutations and molecular abnormalities specific to each subtype of non-small cell lung cancer, as well as the development of resistance mechanisms to targeted therapies. Additionally, the heterogeneity of non-small cell lung cancer poses a challenge in delivering personalized treatment approaches. Furthermore, the age and gender of the patient may also influence treatment decisions and outcomes. In present review, we have tried to summarize the current strategies being adapted in treatment of non-small cell lung carcinoma along with the hurdles associated with each therapy that needs to be addressed
Keywords:
Non-small cell carcinoma, NSCLC, Targeted therapy, Immunotherapy, Lung Cancer, KRAS, MET, Tumour, Adenocarcinoma, EGFR, Co-mutations.DOI
https://doi.org/10.25004/References
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. doi:10.3322/caac.21208
Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ. American Cancer Society guidelines for the early detection of cancer. CA: a cancer journal for clinicians. 2002 Jan;52(1):8-22.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024 May;74(3):229-63.
Kowalczyk A, Jassem J. Multidisciplinary team care in advanced lung cancer. Transl Lung Cancer Res. 2020;9(4):1690-1698. doi:10.21037/tlcr.2019.11.33
Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624-639. doi:10.1038/s41571-023-00798-3
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers - A review. Eur J Cancer. 2012;48(9):1299-1311. doi:10.1016/j.ejca.2012.03.007
Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control. 2008;17(3):198-204. doi:10.1136/tc.2007.022582
Brambilla E, Travis WD, Colby T V., Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. European Respiratory Journal. 2001;18(6):1059-1068. doi:10.1183/09031936.01.00275301
Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5(SUPPL.4). doi:10.3978/j.issn.2072-1439.2013.07.10
Tanoue LT, Detterbeck FC. New TNM classification for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009;9(4):413-423. doi:10.1586/era.09.11
Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SD. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: A review. Radiation Oncology. 2014;9(1). doi:10.1186/1748-717X-9-210
Van Den Berg LL, Klinkenberg TJ, Groen HJM, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. Journal of Thoracic Oncology. 2015;10(5):826-831. doi:10.1097/JTO.0000000000000483
Timmerman R, Paulus R, Galvin J, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA. 2010;303(11):1070-1076. doi:10.1001/jama.2010.261
Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II Study. Int J Radiat Oncol Biol Phys. 2009;75(3):677-682. doi:10.1016/j.ijrobp.2008.11.042
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology. 1982 Dec 1;5(6):649-56.
Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. Journal of Clinical Oncology. 2010;28(6). doi:10.1200/JCO.2009.21.9618
Sculier JP. Anticancer treatment for advanced non-small cell lung cancer. Breathe. 2011;8(2):125-133. doi:10.1183/20734735.005011
Scagliotti G V., De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2002;20(21). doi:10.1200/JCO.2002.02.068
Kelly K, Crowley J, Bunn J, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. Journal of Clinical Oncology. 2001;19(13). doi:10.1200/JCO.2001.19.13.3210
Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2002;346(2). doi:10.1056/nejmoa011954
Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group. Journal of Clinical Oncology. 2003;21(16). doi:10.1200/JCO.2003.12.046
Pisters KMW, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. Journal of Clinical Oncology. 2007;25(34). doi:10.1200/JCO.2007.14.1226
Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 SUPPL.). doi:10.1378/chest.07-1378
Dempke WCM, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67(3):257-274. doi:10.1016/j.lungcan.2009.10.012
Araghi M, Mannani R, Heidarnejad maleki A, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(1). doi:10.1186/s12935-023-02990-y
Zhou J. Advances and Prospects in Cancer Immunotherapy. New J Sci. 2014;2014. doi:10.1155/2014/745808
Paulsen EE, Kilvaer TK, Rakaee M, et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunology, Immunotherapy. 2017;66(11). doi:10.1007/s00262-017-2039-2
Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Anti-pd1/pd-l1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations. Int J Mol Sci. 2021;22(12). doi:10.3390/ijms22126288
Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. Journal of Clinical Oncology. 2021;39(7). doi:10.1200/JCO.20.01605
Barlesi F, Garon EB, Kim DW, et al. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC. Journal of Thoracic Oncology. 2019;14(5). doi:10.1016/j.jtho.2019.01.016
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. Journal of Clinical Oncology. 2019;37(7). doi:10.1200/JCO.18.00149
Mizuno T, Katsuya Y, Sato J, Koyama T, Shimizu T, Yamamoto N. Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Front Oncol. 2022;12. doi:10.3389/fonc.2022.925938
Suraya R, Tachihara M, Nagano T, Nishimura Y, Kobayashi K. Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. Cancer Manag Res. 2022;14. doi:10.2147/CMAR.S366738
Ilie M, Hofman P. Atezolizumab in advanced non-small cell lung cancer. J Thorac Dis. 2017;9(10). doi:10.21037/jtd.2017.09.73
Xie Q, Zheng H, Su N, Li Q. Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China. BMJ Open. 2022;12(8). doi:10.1136/bmjopen-2022-061592
Liang H, Chen Q, Hu Z, et al. Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis. Ann Transl Med. 2022;10(6). doi:10.21037/atm-22-764
Ye H, Zhao J, Xu X, Zhang D, Shen H, Wang S. Role of adenosine A2a receptor in cancers and autoimmune diseases. Immun Inflamm Dis. 2023;11(4). doi:10.1002/iid3.826
Garcia-Lorenzo E, Moreno V. Targeting the adenosine 2A receptor in non-small cell lung cancer: shooting with blank bullets? Transl Lung Cancer Res. 2023;12(4). doi:10.21037/tlcr-23-38
Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clin Res Rep. 2021;2(4). doi:10.1016/j.jtocrr.2021.100149
Zhang H, Li M, Kaboli PJ, et al. Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy. International Journal of Biological Markers. 2021;36(2). doi:10.1177/17246008211005473
Djureinovic D, Wang M, Kluger HM. Agonistic cd40 antibodies in cancer treatment. Cancers (Basel). 2021;13(6). doi:10.3390/cancers13061302
Nicolson M. ES05.01 Lung Cancer Survival: Progress and Challenges. Journal of Thoracic Oncology. 2019;14(10). doi:10.1016/j.jtho.2019.08.087
Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3). doi:10.1124/pr.111.005637
Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World J Clin Oncol. 2016;7(1). doi:10.5306/wjco.v7.i1.106
Mariani M, Karki R, Spennato M, et al. Clas- III β-tubulin in normal and cancer tissues. Gene. 2015;563(2). doi:10.1016/j.gene.2015.03.061
Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22(47 REV. ISS. 6). doi:10.1038/sj.onc.1206934
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance. 2019;2(2):141-160. doi:10.20517/cdr.2019.10
Zhang Y, Yang SH, Guo XL. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer. Biomedicine and Pharmacotherapy. 2017;96. doi:10.1016/j.biopha.2017.10.041
Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clinical Cancer Research. 2010;16(1). doi:10.1158/1078-0432.CCR-09-1321
Ashrafizadeh M, Mirzaei S, Hashemi F, et al. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomedicine and Pharmacotherapy. 2021;141. doi:10.1016/j.biopha.2021.111824
Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579). doi:10.1038/nature16064
Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12. doi:10.1186/1471-2407-12-91
Marabese M, Ganzinelli M, Garassino MC, et al. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015;6(32). doi:10.18632/oncotarget.5607
Beganovic S. Clinical significance of the KRAS mutation. Bosn J Basic Med Sci. 2009;9(SUPPL.). doi:10.17305/bjbms.2009.2749
Reita D, Pabst L, Pencreach E, et al. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance. Cancers (Basel). 2022;14(5). doi:10.3390/cancers14051321
Błach J, Wojas-Krawczyk K, Nicoś M, Krawczyk P. Failure of immunotherapy—The molecular and immunological origin of immunotherapy resistance in lung cancer. Int J Mol Sci. 2021;22(16). doi:10.3390/ijms22169030
Zhao L ping, Hu J hu, Hu D, et al. Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. Biomedicine and Pharmacotherapy. 2022;150. doi:10.1016/j.biopha.2022.112949
Published

How to Cite
Issue
Section
Copyright (c) 2025 Swati Kurtkoti, Dr. Harshaben V. Patel

This work is licensed under a Creative Commons Attribution 4.0 International License.